← boothcheck

Is DLB overvalued?

boothcheck doesn't label DLB overvalued or undervalued and publishes no house fair value, target price, or buy/sell rating. Individual model outputs and user-controlled scenarios are analytical inputs, not Boothcheck targets. In the published model solve dated 2026-08-30T04:06:24.299Z, anchored at $61.50, DLB is priced for growth of +15.0%. Asset, earnings-power and peer-multiple models all land far below the price; ONLY the growth-DCF reaches it. The bet is durable compounding the static frames structurally cannot price (a moat/durability premium). The report narrative was composed 2026-07-25. The more the price assumes beyond what DOLBY LABORATORIES, INC. has actually delivered, the more has to go right to justify it. Whether that bar is too high is your call, and the full bull and bear cases are in the report.

Derived from DOLBY LABORATORIES, INC.'s SEC EDGAR filings via a reverse-DCF inversion. Last analyzed July 25, 2026.

Implied growth+15.0%
For about
Held margin (input)
Margin today
Price vs asset value2.48x
Price vs earnings power2.10x
Price vs peer multiples1.62x
Price vs forward growth1.17x
Read the full DLB report →
Get boothcheck's read on what DLB's price is betting on, in your inbox when it moves. No hype, no spam.
Free. Informational only, not investment advice. Unsubscribe anytime.

For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.